《新股表現》開拓藥業(09939.HK)暗盤高開19%報24元
根據輝立交易平台顯示,明天掛牌的開拓藥業-B(09939.HK)暗盤高開19%報24元欠承接,曾回順至20.5,現造22.4元,較上市價20.15元,高11%,成交113萬股。
開拓藥業為仍未有盈利生物科技公司。是次來港上市共發售近9,235萬股,並已引入格力金控投資、Foresight Orient Global Superior Choice SPC、Highlight Medical及Cherry Cheeks HK四名基石投資者合共認購4,423.5萬股;其中10%公開發售獲逾550倍超購,已啟動回撥機制佔比增至50%,認購一手中籤率僅10%;股份以招股範圍(17.8-20.15元)定價,料集資淨額17.48億元,主要用於核心產品普克魯胺與福瑞他恩開發和商業化、分配給其他臨床階段在研藥物進行中及計劃臨床試驗,以及用於臨床前階段在研藥物等。上市保薦人華泰國際。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.